FDA Adds Eye Risk Warning to GLP-1 Labels After Review of 126 Trials

The FDA is mandating new warnings on GLP-1 drugs like Ozempic regarding a possible increased risk of a rare eye disease, based on a review of 126 clinical trials involving over 134,000 patients. The data is not fully conclusive, indicating uncertainty about the causal link. This regulatory action could affect prescribing patterns and manufacturer liability, with potential implications for the pharmaceutical sector.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works